 By John Vandermosten, CFA NASDAQ:ACHV On Monday, Achieve Life Sciences, Inc. NASDAQ:ACHV updated the investment community on the status of New Zealands RAUORA 1 study, which was expected to announce completion in the months leading up to the September SRNT conference. While full results were not provided, the studys principal investigator did announce that cytisinicline was as good as 